• AZD6482 as a Precision Tool for PI3Kβ Inhibition in Disease

  2026-06-19

  Discover how AZD6482, a potent PI3Kβ inhibitor, enables advanced mechanistic studies across metabolic, thrombotic, and signaling research. This article uniquely connects the compound’s selective inhibition profile with novel assay strategies and translational insights.

• Tacalcitol Monohydrate Potentiates 5-FU in Colorectal Cancer

  2026-06-18

  This article analyzes a pivotal study demonstrating that tacalcitol monohydrate, a synthetic analog of vitamin D3, enhances the efficacy of 5-fluorouracil (5-FU) in colorectal cancer cell models via downregulation of thymidylate synthase. The findings clarify tacalcitol's VDR-dependent mechanism and provide practical guidance for oncology researchers optimizing combinatorial therapies.

• BRD4770: G9a Histone Methyltransferase Inhibitor in Cancer R

  2026-06-18

  BRD4770 offers targeted, reliable G9a histone methyltransferase inhibition, enabling precise dissection of H3K9 methylation's role in tumorigenesis and senescence. Its robust performance in challenging models, like PANC-1 cells, makes it a go-to tool for epigenetic and cancer biology researchers seeking reproducible, actionable insights.

• Y-27632 Dihydrochloride: Applied ROCK Inhibitor Workflows

  2026-06-17

  Y-27632 dihydrochloride empowers reproducible cytoskeletal, stem cell, and tumor invasion assays through potent, selective ROCK1/2 inhibition. This guide details best practices, protocol nuances, and troubleshooting strategies to unlock advanced applications in cancer and regenerative research.

• circRHOBTB3-Mediated Suppression of Prostate Cancer Metastas

  2026-06-17

  The referenced study uncovers circRHOBTB3 as a key tumor suppressor in metastatic prostate cancer, acting by sequestering NONO and downregulating MAOA expression. These findings clarify a novel RNA-mediated mechanism of metastasis inhibition, providing new molecular targets for disease intervention.

• Machine Learning for MoA Prediction Across Cancer Cell Lines

  2026-06-16

  Warchal et al. systematically evaluate how machine learning classifiers predict compound mechanisms of action (MoA) using high-content imaging data from genetically diverse cancer cell lines. Their findings clarify the strengths and limitations of convolutional neural networks versus ensemble tree models, with important implications for translational screening and phenotypic drug discovery workflows.

• Improving In Vitro Drug Response Evaluation in Cancer Resear

  2026-06-16

  Schwartz's dissertation advances in vitro cancer drug testing by dissecting distinct metrics for drug-induced cell proliferation arrest and cell death, revealing their non-interchangeability. These methodological refinements enhance the precision of preclinical evaluation, supporting improved translational strategies for agents like novel PARP inhibitors.

• Linoleic Acid–PPARα Axis Drives TF Expression in pLELC Progr

  2026-06-15

  This study uncovers a novel tumorigenic mechanism in primary pulmonary lymphoepithelioma-like carcinoma (pLELC), demonstrating that linoleic acid promotes tumor progression by upregulating tissue factor (TF) through PPAR-α signaling. The findings position PPARα and TF as promising therapeutic targets and provide a mechanistic link between lipid metabolism and tumor microenvironment modulation.

• Cell Divisions Refine Tissue Boundaries in Drosophila Embryo

  2026-06-15

  This study demonstrates that cell divisions in the Drosophila embryo not only challenge but also refine tissue boundaries by enhancing tissue fluidity. Using quantitative imaging and mathematical modeling, the research uncovers a mechanism by which proliferation-driven cell rearrangements maintain sharp interfaces between distinct cell populations, with potential implications for developmental biology and cancer research.

• Myriocin (SKU B6064): Optimizing Sphingolipid Metabolism Ass

  2026-06-14

  This article delivers practical, scenario-driven guidance for biomedical researchers leveraging Myriocin (SKU B6064) as a selective serine palmitoyltransferase inhibitor. Through real-world laboratory Q&As, it addresses experimental design, protocol optimization, and vendor selection, situating Myriocin as a robust, data-backed solution for cell viability, cancer, and metabolic research workflows.

• (S)-(+)-Ibuprofen: Precision COX Inhibition and Environmenta

  2026-06-13

  (S)-(+)-Ibuprofen stands out as a selective COX inhibitor with potent anti-inflammatory effects and unique environmental considerations. This article provides an in-depth exploration of its pharmacological mechanisms, assay optimization, and the emerging need for responsible usage in research.

• Targeting FOXO3 to Suppress Metabolic Reprogramming in HCC

  2026-06-12

  This study demonstrates that FOXO3 acts as a tumor suppressor in hepatocellular carcinoma (HCC) by coordinately inhibiting glycolysis and glutaminolysis. Mechanistic insights reveal FOXO3 represses YAP-driven metabolic programs, offering a promising strategy for metabolic intervention in HCC.

• Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP): Precision Repor

  2026-06-12

  Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) sets a new benchmark for bioluminescent reporter assays, combining ultra-low immunogenicity with unparalleled translational efficiency. Its unique design empowers researchers to achieve consistent, high-sensitivity readouts in gene expression, viability, and in vivo imaging studies, even under challenging conditions.

• Ro 3306: Precision CDK1 Inhibitor for G2/M Cell Cycle Arrest

  2026-06-11

  Ro 3306 is a selective CDK1 inhibitor that empowers researchers to arrest cancer cells at the G2/M boundary with high reproducibility, unlocking advanced studies of cell cycle regulation, DNA repair, and cell synchronization. Leveraging new mechanistic insights into mTORC1 oscillations and checkpoint control, this article details optimized experimental workflows, troubleshooting strategies, and practical innovations for robust cell cycle research.

• MIZ1-TMBIM4 Axis Safeguards IgG1+ B Cell Selection in Germin

  2026-06-11

  This study reveals a unique, isotype-specific survival mechanism for IgG1+ germinal center B cells, mediated by the transcription factor MIZ1 and its induction of the anti-apoptotic protein TMBIM4. These findings advance our understanding of humoral immunity and provide a mechanistic basis for antibody affinity maturation, informing both immunology and apoptosis signaling research.

15985 records 1/1066 page Next 12345 下5页 Last page